Analysts Expect Encompass Health Co. (NYSE:EHC) Will Post Quarterly Sales of $1.32 Billion

Equities research analysts expect Encompass Health Co. (NYSE:EHCGet Rating) to post $1.32 billion in sales for the current fiscal quarter, according to Zacks. Five analysts have provided estimates for Encompass Health’s earnings. The highest sales estimate is $1.34 billion and the lowest is $1.29 billion. Encompass Health reported sales of $1.23 billion during the same quarter last year, which indicates a positive year over year growth rate of 7.3%. The company is expected to announce its next earnings results after the market closes on Monday, January 1st.

On average, analysts expect that Encompass Health will report full-year sales of $5.43 billion for the current year, with estimates ranging from $5.32 billion to $5.46 billion. For the next fiscal year, analysts forecast that the firm will report sales of $5.88 billion, with estimates ranging from $5.72 billion to $5.97 billion. Zacks Investment Research’s sales averages are a mean average based on a survey of sell-side research firms that cover Encompass Health.

Encompass Health (NYSE:EHCGet Rating) last announced its quarterly earnings data on Tuesday, February 1st. The company reported $0.97 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.06 by ($0.09). The company had revenue of $11.32 billion during the quarter, compared to analysts’ expectations of $1.31 billion. Encompass Health had a net margin of 8.05% and a return on equity of 19.20%. The business’s quarterly revenue was up 832.0% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.93 EPS.

EHC has been the subject of several recent research reports. Truist Financial lifted their price objective on Encompass Health from $78.00 to $85.00 in a research note on Thursday. Deutsche Bank Aktiengesellschaft decreased their target price on Encompass Health from $95.00 to $80.00 in a research note on Thursday, January 20th. Zacks Investment Research upgraded Encompass Health from a “sell” rating to a “hold” rating and set a $76.00 target price for the company in a research note on Monday. Credit Suisse Group decreased their target price on Encompass Health from $84.00 to $77.00 in a research note on Thursday, February 3rd. Finally, StockNews.com initiated coverage on Encompass Health in a research note on Thursday, March 31st. They set a “hold” rating for the company. Two analysts have rated the stock with a hold rating, seven have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Buy” and a consensus target price of $83.89.

Shares of EHC traded down $0.85 during midday trading on Friday, hitting $71.74. The company had a trading volume of 10,572 shares, compared to its average volume of 898,393. The company’s 50-day simple moving average is $67.96 and its 200-day simple moving average is $65.23. The company has a debt-to-equity ratio of 1.38, a quick ratio of 1.23 and a current ratio of 1.23. The firm has a market capitalization of $7.13 billion, a P/E ratio of 17.47, a P/E/G ratio of 2.48 and a beta of 0.99. Encompass Health has a 1 year low of $56.31 and a 1 year high of $89.68.

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, April 18th. Shareholders of record on Friday, April 1st will be paid a $0.28 dividend. The ex-dividend date is Thursday, March 31st. This represents a $1.12 dividend on an annualized basis and a yield of 1.56%. Encompass Health’s dividend payout ratio is presently 27.25%.

Hedge funds and other institutional investors have recently bought and sold shares of the business. Whittier Trust Co. purchased a new stake in shares of Encompass Health in the fourth quarter valued at about $26,000. Signaturefd LLC boosted its holdings in shares of Encompass Health by 58.9% in the fourth quarter. Signaturefd LLC now owns 499 shares of the company’s stock valued at $33,000 after acquiring an additional 185 shares in the last quarter. Parallel Advisors LLC boosted its holdings in shares of Encompass Health by 103.1% in the fourth quarter. Parallel Advisors LLC now owns 532 shares of the company’s stock valued at $35,000 after acquiring an additional 270 shares in the last quarter. Covestor Ltd purchased a new stake in shares of Encompass Health in the fourth quarter valued at about $38,000. Finally, First Horizon Advisors Inc. boosted its holdings in Encompass Health by 100.8% during the third quarter. First Horizon Advisors Inc. now owns 741 shares of the company’s stock worth $39,000 after buying an additional 372 shares in the last quarter. Institutional investors own 92.35% of the company’s stock.

Encompass Health Company Profile (Get Rating)

Encompass Health Corp. engages in the provision of post-acute healthcare services. It operates through the Inpatient Rehabilitation and Home Health and Hospice segments. The Inpatient Rehabilitation segment operates inpatient rehabilitation hospitals that provide rehabilitative treatment and care to patients who are recovering from stroke and other neurological disorders, cardiac and pulmonary conditions, brain and spinal cord injuries, complex orthopedic conditions and amputations.

See Also

Get a free copy of the Zacks research report on Encompass Health (EHC)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Encompass Health (NYSE:EHC)

Receive News & Ratings for Encompass Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Encompass Health and related companies with MarketBeat.com's FREE daily email newsletter.